Puissance Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Puissance Capital Management LP
CRD #175226
SEC #801-135328
CIK #0001658437
AUM 45.0 M (2026-01-13)
Employees 2 (50% Investors, 50% Brokers)
Fees
Minimum
Phone212-878-3702
Address
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
170136102683402010201520212027
Fees and Compensation — Form ADV Part 2A (1/13/2026) [Brochure]
Item 5 - Fees and Compensation

Puissance or its affiliates will receive a management fee and performance-based compensation
from Clients. The Firm’s management fee is generally equal to 2.00% of assets under
management per annum and performance-based compensation is generally equal to 20% of
the appreciation in the net asset value of each account during each year. Fee arrangements
may be amended by agreement between Puissance and each Client or investor. The exact
compensation structure will be set forth in the relevant investment management agreement
with each Client and each investor, as the case may be.

Puissance expects that the Funds will be responsible for investment-related expenses
(including brokerage (see Item 12 below), as well as their organizational and offering expenses.

The expenses charged to any Managed Accounts will be determined on a case-by-case basis.

To the extent that Puissance allocates Clients’ capital to money market funds or exchange-
traded funds, Clients would indirectly incur similar fees and expenses as these funds in turn
pay similar fees and expenses to their investment managers and other service providers.

Item 6 - Performance Fees and Side-by-Side Management

Puissance or its affiliates will receive performance-based compensation from Clients, which
will be based on a percentage of capital appreciation of their assets.

Puissance Capital Management LP                                             Form ADV Part 2A

The terms of the performance-based compensation may differ among the Clients. This may
result in a conflict of interest when allocating opportunities among Clients, as Puissance may
have an incentive to favor Clients that have higher performance-based compensation. To
avoid such a conflict of interest, Puissance will develop documented procedures for allocating
opportunities among Clients, which will not take into account the performance-based
compensation.

As management fees and performance-based compensation will be based directly on Clients’
net asset values, Puissance may have a conflict of interest in valuing the assets held in Client
accounts. Puissance will follow documented valuation policies and consult with each Client’s
third-party administrator, as applicable, in order to mitigate this risk.
Account Minimums and Types of Clients — Form ADV Part 2A (1/13/2026) [Brochure]
Item 7 - Types of Clients

Puissance will provide investment advice to clients that are private funds, high net worth
individuals or other institutional investors. Investors in the Funds are generally expected to
be institutional investors and high net worth individuals that qualify as “accredited investors”
(as defined in Rule 501 under the Securities Act of 1933, as amended) and “qualified
purchasers” (as defined under the Investment Company Act of 1940, as amended). The
minimum initial investment in the Funds is expected to be $500,000, subject to Puissance’s
discretion to accept lesser amounts. The minimum initial investment for high net worth
individuals is expected to be $100,000. Puissance will determine the minimum investment for
a Managed Account on a case by case basis.
Sector Form 13F Holdings Value ($M)
Scynexis Inc 1.4
Corvus Pharmaceuticals Inc 0.2
 
 
 
 
 
 
 
 
 
Holdings by Sector ($M)
2502001501005002018201920202021
Type Form D Funds Date Sold AUM
HF PCM AI Opportunities Fund [2019-03-14] 1.0 M 12.0 M
Filed 2025-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Puissance Cross-Border Opportunities III LLC 2018-01-25 3.0 M
PE Puissance Cross-Border Opportunities II LLC 2018-01-25 8.3 M
PE Puissance Cross-Border Opportunities IV LLC 2018-01-25 2.0 M
PE Puissance Cross Border Opportunities V LLC 2018-01-25 0.2 M
PE Puissance Life Science Opportunities Fund VII 2018-01-25 0.0 M
HF Puissance China Market Neutral Master Fund LP [2017-03-30] 44.8 M 1.9 M
Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Puissance Cross-Border Opportunities I LP 2017-03-30 31.2 M
HF Puissance Asia Master Fund LP [2015-07-09] 10.0 M 8.5 M
Filed 2015-06-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Puissance Capital Master Fund LP [2015-07-09] 44.8 M 80.7 M
Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 33.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 1 12.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 45.0
By Discretionary
Discretionary 3 45.0
Non-Discretionary 0 0.0
Total 3 45.0
By Non-United States Persons
Non-United States Persons 45.0
United States Persons 0.0
Total 3 45.0
Form D Directors Role # Filings # Firms 2011 - 2026
Ted Wang Director, Executive Officer 19 3
Puissance Capital Fund GP LLC Executive Officer 2 1
Puissance Capital Management LP Executive Officer 2 1
Hanchen Jin Director 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001658437]
3 [0001658437]
4 [0001658437]
SC 13D [0001658437]
Form 13D/13G Filer Form 13D/13G Subject Filed
Puissance Capital Management LP ViewRay Inc [2017-01-25]
Firm Profile (Form ADV)
ServesInstitutional, Retail
Fund TypesHedge Fund, Private Equity
LEI254900XD1KV0Z9RJYC26
Form 3/4/5 Subject 2011 - 2026
Puissance Life Science Opportunities Fund VI
Puissance Capital Fund GP LLC
Puissance Capital Management LP
Bellerophon Therapeutics LLC
Wang Theodore T
Puissance Capital Management GP LLC
Puissance Cross-Border Opportunities II LLC
ChronoScale Holdings Corp
Puissance Cross-Border Opportunities III LLC
Puissance Cross-Border Opportunities IV LLC
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-10-13 Sell 1,076,841 $0.10 107,684
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-06-07 Sell 134,421 $0.83 111,569
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-05-18 Sell 560,000 $9.46 5,297,600
Bellerophon Therapeutics LLC BLPH
Common Stock
2021-06-07 Grant 8,189 $4.00 32,756
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
2021-04-26 Grant 380,950 $0.00
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
2021-04-26 Grant 304,286 $0.00
Bellerophon Therapeutics LLC BLPH
Common Stock
2021-04-26 Grant 609,231 $4.00 2,436,924
ChronoScale Holdings Corp EKSO
Common Stock
2020-07-23 Grant 7,383 $0.00
Bellerophon Therapeutics LLC BLPH
Common Stock
2020-05-21 Grant 1,153,846 $13.00 14,999,998
Bellerophon Therapeutics LLC BLPH
Common Stock
2020-04-17 Other 553,250
ChronoScale Holdings Corp EKSO
Common Stock
2020-03-02 Other 8,918,898
ChronoScale Holdings Corp EKSO
Stock Option (right to buy) · derivative
2020-01-16 Grant 136,496 $0.00
ChronoScale Holdings Corp EKSO
Common Stock
2020-01-16 Grant 19,445 $0.45 8,750
Tracon Pharmaceuticals Inc TCON
Common Stock
2019-12-09 Sell 340,134 $2.92 993,191
Tracon Pharmaceuticals Inc TCON
Common Stock
2019-12-05 Sell 43,996 $3.05 134,188
Tracon Pharmaceuticals Inc TCON
Common Stock
2018-11-29 Buy 4,326 $1.13 4,888
Tracon Pharmaceuticals Inc TCON
Common Stock
2018-11-29 Sell 4,326 $1.21 5,234
ChronoScale Holdings Corp EKSO
Common Stock
2018-08-03 Grant 19,179 $1.79 34,330
ChronoScale Holdings Corp EKSO
Employee Stock Option (right to buy) · derivative
2018-08-03 Grant 41,000 $0.00
Comparable Firms State AUM
Altai Capital Management LP
49.8 M
Remy Investors & Consultants Incorporated
CA
Third Security LLC
VA
BRS Financial LLC
AR
Fortius Financial Advisors LLC
UT
Spruce Investment Advisors LLC
CT
Income Partners Asset Management HK Limited
Red Hook Management LLC
NJ
Summit Capital Management LLC
WA
Prairie Capital Management LLC
MO
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com